InVivo Therapeutics Holdings Corp. (OTC:NVIV), a pre-revenue medical technology start-up, could end up paying its CEO Frank Reynolds more than $775,000 in salary, benefits and bonuses during 2011. Reynolds, who founded the company in 2005 in Cambridge, Mass., using technology acquired from Mass. Institute of Technology scientist Robert Langer, will get a 27 percent raise added to his base salary, going from $375,000 to $477,000 per year.
InVivo Therapeutics Holding Corp. (OTC:NVIV) closed a private placement of 13 million units of stock and warrants, topping its $10 million goal with gross proceeds of $13 million.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
InVivo Therapeutics Corp. (OTC:NVIV) inked a lease for a manufacturing and development plant in Medford, Mass., as it gears up for possible human clinical trials of its regenerative spine treatment. Cambridge, Massachusetts-based InVivo netted about $9 million as part of a reverse merger last week with a holding company, Design Source Inc. Stock in the […]
InVivo Therapeutics Corp. (OTC:NVIV) closed a reverse merger with its holding company, taking itself public under the stock symbol “NVIV” on the OTC exchange as of tomorrow. The Cambridge, Massachusetts-based company also announced a private stock placement that will net it $8.8 million. InVivo is hoping for a nod from the Food & Drug Administration […]